[7] For weight management, NICE (TA875) recommends semaglutide 2.4 mg for adults with a BMI of 35 kg/m or greater (or 30 kg/m or greater with at least one weight-related comorbidity), or 30 kg/m (or 27.5 kg/m with comorbidities) for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean family backgrounds
Those with a history of severe gastrointestinal issues Slowing digestion helps control hunger and reduce calorie intake, and Semaglutide does that
Your physician may make the proper referrals to receive further treatments, if they are right for you
Participants lost an average of 14.9% of their body weight
For example, a phase IIb, double-blind, placebo-controlled study was conducted in adults with T2DM and MASH with fibrosis (F1-F3) on stable treatment with GLP-1 receptor agonists to receive efruxifermin 50 mg or placebo once weekly for 12 weeks
Food and Drug Administration (FDA) for reducing the risk of cardiovascular problems and worsening kidney disease in patients with chronic kidney disease and type 2 diabetes